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Human rhinoviruses are the primary etiological agent of the common cold. This infection can be mild
and self-limiting in immunocompetent hosts, but can be associated with bronchiolitis in infants, pneu-
monia in the immunosuppressed and exacerbations of pre-existing pulmonary conditions such as asthma
or chronic obstructive pulmonary disease. Many of these conditions can place significant economic costs
upon healthcare infrastructure. There is currently no licensed vaccine for rhinovirus, as the large variety
of rhinovirus serotypes has posed significant challenges for research. In this review, we discuss current
knowledge around antiviral drugs and small molecule inhibitors of rhinovirus infection, as well as antivi-
ral host defense peptides as exciting prospects to approach the development of novel therapeutics which
target human rhinovirus.
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Background
Human rhinoviruses
Human rhinoviruses (RVs) are small (27 nm), nonenveloped, ssRNA viruses of the Picornaviridae family. More
than 160 strains of RV have been identified and classified into three genetic clades (A, B and C) according to
sequence similarity [1]. Competition assays for cellular binding sites have further grouped RVs into major group or
minor group viruses depending on the use of ICAM-1 or LDLR as receptors [1]. Recently, the asthma susceptibility
gene product, CDHR3, has been shown to mediate RV-C binding and replication [2].
RV infections are mainly transmitted due to direct contact or via fomite, with inoculation to the eye or nose
from the fingertip. RV predominantly infects cells of the upper respiratory tract, although RV RNA has also been
found in lower airways after experimental RV infection [3]. In situ hybridization experiments have shown that RV
initially replicates in small groups of airway epithelial cells without induction of visible cytopathic effects and cell
destruction [4,5]. RV infection does, however, compromise epithelial barrier integrity which may cause an increased
translocation of pathogens and complications of respiratory diseases [6].
RV is the etiological agent of one-half to two-thirds of common colds [4,7]. Children can be infected from 8- to
12-times per year, while adults can be infected 2- to 3-times per year, with peaks of infection occurring throughout
the year [8]. While mild and self-limiting in immunocompetent hosts, RV infection is associated with bronchiolitis
in infants, pneumonia in the immunosuppressed and exacerbations of pre-existing pulmonary conditions such as
asthma or chronic obstructive pulmonary disease [9,10,11,12,13]. Furthermore, children who experience wheezing as
a result of RV infection are at increased risk of subsequently developing asthma [14]. Many of these conditions can
require hospitalization and place significant economic costs upon healthcare infrastructure.
The antigenic diversity displayed by the large variety of RV serotypes has posed significant challenges for research
into an effective and universal RV vaccine [15]. Currently there are in excess of ten clinical trials currently ongoing
in the USA alone in an attempt to develop effective preventative vaccinations for the infection [16]. The fact that
around 90% of RV serotypes bind to human ICAM-1 but cannot bind to the murine ICAM-1 receptor has, in the
past, limited the availability and validity of animal models of infection [17]. However, the development of mouse-
human ICAM-1 chimeras and other mouse models to study exacerbations induced by human RV, together with the
availability of human experimental infections will provide avenues toward developing better therapeutics [18,19]. In
Future Virol. (Epub ahead of print) ISSN 1746-079410.2217/fvl-2018-0016 C© 2018 AbbVie Inc.
Review Casanova, Sousa, Stevens & Barlow
addition, the significant morbidities and associated economic costs attributed to RV infections would lend weight
to a global effort into the full characterization of different RV strains. Thus, the development of effective antivirals
against the widest possible number of RV serotypes is urgently required.
Antiviral drugs
The number of established chemotherapeutic options for viral infections is still relatively low, and studies have
been undertaken with a view to characterizing the anti-RV activity of drugs already licensed for use against other
infections. There have been in excess of 90 antiviral drugs used for the medical treatment of viral infections, and
these have been categorized into 13 functional groups (reviewed in [20]). The viral infections with antiviral treatment
options include HIV, hepatitis B and C virus, herpesvirus, influenza virus, human cytomegalovirus, varicella-zoster
virus, respiratory syncytial virus (RSV) and human papillomavirus. While none of these drugs have been licensed
for use in RV infection, a number of existing therapeutics have been demonstrated to have antiviral activity against
a number of RV serotypes and thus are exciting prospects for therapeutic use in this infection.
Ribavirin is a synthetic guanosine nucleoside that can interfere with the synthesis of viral mRNA. It is frequently
used as an effective therapeutic in combination with pegylated IFNα-2a for the treatment of hepatitis C infection
and has also been used individually by clinicians in the treatment of severe lower respiratory tract infections caused
by RSV [21,22]. Other infections caused by respiratory pathogens such as adenovirus have also been treated by
ribavirin, normally in patients that are immunocompromised or those who have received bone marrow or stem
cell transplants [23]. Coronaviruses associated with severe acute respiratory syndrome (SARS-CoV) or Middle East
respiratory syndrome have also been studied in the context of ribivirin therapy, although the outcomes have been
mixed, and conjunctive therapy with pegylated IFNα-2a has again been suggested [24,25]. In addition, ribavirin
has also been utilized in the treatment of several viral hemorrhagic fevers, caused by pathogens such as hantavirus
and Lassa virus, but also in the treatment of nairovirus, the cause of the tick-borne disease Crimean–Congo
hemorrhagic fever [26,27,28]. However, the drug is not reported to be active against Marburg virus, Ebola virus and
dengue virus, and only appears to have limited activity against HSV, but not HIV [29,30,31]. In the context of RV
infection, ribavirin and a number of modified analogs have been shown to have moderate antiviral activity against
RV-13 [32]. RV-87 was also reported to be moderately susceptible to treatment, although other in vitro studies using
alternative serotypes of RV, such as RV-14, have suggested that ribavirin is relatively ineffective [33,34]. However,
clinical reports of ribavirin therapy twinned with the use of IFNα-2a have indicated that combinatorial therapy
could be of value with patients reportedly exhibiting enhanced clearance of RV infections following treatment with
these two compounds [35].
A number of studies have focused upon the effectiveness of the compound pleconaril against humanRV. Pleconaril
(3-(3,5-dimethyl-4-((3-(3-methyl-5-isoxazolyl)propyl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole) is known to
display broad spectrum antiviral activity against a range of viral pathogens. It is known to bind to hydrophobic
pockets within viral capsids, altering binding of the viral pathogen to host cell receptors and blocking uncoating [36].
In RV and others, this is believed to take place in the VP1 protein, the largest and most exposed surface protein
of the capsid [37]. One comprehensive study examined the effectiveness of pleconaril against a selection of five
RV serotypes (RV-2, RV-14, RV-16, RV-39 and RV-Hanks [later serotyped as A21]) and 46 clinical isolates using
in vitro cytopathic effect (CPE) inhibition assays [38]. The study demonstrated that the compound had effective
antiviral activity against the five serotypes (median EC50 of 0.02 μg/ml) and against the majority of the untyped
clinical isolates. Two separate studies also demonstrated findings in accord with this, showing antiviral activity of
pleconaril against RV-14 and RV-87 [33,34]. Interestingly, analysis of several RV serotypes has also assessed structural
features of amino acids that make up the VP1 protein, and has identified several common sequences and mutations
that confer natural resistance to capsid binding compounds such as pleconaril, as well as those that could arise
as a result of antiviral drug treatment [39,40]. A number of human experimental pleconaril administration studies
have found that pleconaril could offer a tangible treatment option for RV infection as volunteers treated with
this drug appeared to show less clinical symptomology and lower recovery of picornaviruses than controls [41,42].
However, varying virus serotype susceptibility to pleconaril did appear to play a significant role in the efficacy of
the treatment and clinical outcome [43]. However, studies into pleconaril analogs with enhanced activity against RV
are still ongoing [44].
A number of other novel capsid binding compounds have shown effective antiviral activity against rhinovirus, and
another capsid binding protein that has generated intense interest is pirodavir. A study of this compound showed
showed antiviral activity against RV-14 and against RV-87 [33,34]. A comprehensive assessment was undertaken by
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Brown et al. (2005), who established that pirodavir had substantial antiviral activity against a range of 15 different
serotypes of RV [45]. Interestingly, RV-45 appeared to be completely resistant to this compound. However, in the
same study, a series of pyridazinylpiperidinyl-based compounds were synthesized and one derivative was also found
to be particularly effective against a number of the RV serotypes [45]. In a similar context, an analog of pirodavir,
termed BTA798 has also shown effective activity against several RV serotypes and has been assessed in Phase II
clinical trials [34,46]. Another capsid binding drug, vapendavir, which has been shown to inhibit enterovirus-71, has
very recently also been utilized in Phase II clinical trials, but at the time of writing, the efficacy of this treatment is
as yet unclear.
The compound rupintrivir, also known as AG7088, is an inhibitor of viral 3C protease, an enzyme that
is virally encoded and essential for RV replication. Studies of rupintrivir in the context of RV infection has
revealed that it exhibits moderate antiviral activity in vitro against a range of RV serotypes, enterovirus-71 and
coxsackievirus [34,47,48,49,50,51]. Additionally, it demonstrated efficacy in a Phase II clinical trial of experimental RV
infection and was well tolerated by human subjects in multiple human exposures [52,53]. Interestingly, a recent study
has also revealed that analogs of rupintrivir based on proline and azetidine modifications to this compound have
also revealed broad spectrum activity against a range of RV serotypes [54]. Of further interest was the observation
that rupintrivir also exhibited in vitro activity against newly discovered human RV C strains [55]. Assessment of the
potential for RV to evolve resistance to rupintrivir has also been conducted, with selection of novel RV variants in
increasing concentrations of the drug displaying minimal to moderate susceptibility reductions [56]. Collectively, it
is clear that this compound, and novel analogs, have potential for the development of novel therapeutics for RV,
but that further in vivo trials are required.
In our literature review, we have also identified a number of other small compounds that have been investigated
as novel inhibitors of RV over the past four decades. These include the compound 2-(3,4-dichlorophenoxy)-5-
nitrobenzonitrile (MDL-860) which showed antiviral activity against RV and other viral pathogens [57,58]. Other
studies have identified novel ((biphenyloxy)propyl) isoxazole derivatives as having activity against RV-2 [59]. A
very recent report describes a series of benzothiophene derivatives [60] that inhibited the replication of a number
of RV serotypes and was proposed to act through viral capsid binding in a similar way to pleconaril. Recently,
three novel epidithiodiketopiperazines (KCN-2,2’-epi-19, KCN-19 and KCN-21) were synthesized that displayed
activity against RV-87 [33]. Interestingly, the antifungal compound itraconozole has recently been found to have in
vitro and in vivo antiviral activity in RV infection [61]. This was potentially due to inhibition of cellular cholesterol
trafficking, a process the authors suggest, in accord with another study [62], is essential for RV replication. This
activity was retained when assessing the antiviral activity of itraconozole-loaded microemulsion droplets as carriers
for the drug [63], Indeed, antiviral nanoparticles have been proposed to be excellent candidates for the development
of antiviral therapeutics as their activity can extend across a broad range of pathogens [64], although further
investigation on the in vivo effects of different nanoparticle formulations is required, as we have recently shown
carbon nanoparticles to be capable of inhibiting the antiviral effects of the human cathelicidin, LL-37, toward RV
in vitro [65].
At last, in vitro studies and clinical trials have suggested that the red seaweed polysaccharide, carrageenan, has
antiviral activity against RV both in vitro and in vivo. Iota-carrageenan, a sulphated variety, was demonstrated to
prevent the replication of RV-1A, 2, 8, 14, 16, 83 and 84 in nasal epithelium [66]. A clinical trial examining the
effect of iota-carrageenan containing nasal spray found that patients found to be positive for RV infection and
treated with nasal spray demonstrated a significant reduction in the duration of symptoms and enhanced resolution
of the infection when compared with placebo control [67].
Host defense peptides
Host defense peptides (HDPs; also known as antimicrobial peptides) are key effector molecules of the innate
immune response [68]. These peptides are found in many vertebrate and invertebrate organisms and display broad
antimicrobial potential, acting directly on viruses and bacteria. In humans and other mammals, there are two
primary families of HDPs that have been well characterized in terms of antimicrobial activity; cathelicidins and
defensins.
HDPs can be expressed by leukocytes and epithelial cells, while being relatively unaffected by modern drug
resistance mechanisms [69]. In addition to their powerful direct antiviral and antibacterial activity, it has also been
demonstrated that these peptides possess immunomodulatory and inflammomodulatory activity and they can
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alter host cellular responses to viral infection [70]. As such, HDPs represent an exciting opportunity for naturally
occurring or synthetic peptide derivatives to be used as novel therapeutic approaches for viral infection [71].
Cathelicidins are a well characterized family of HDPs with some of the most powerful antimicrobial and
immunomodulatory activities. Cathelicidins are a highly conserved family of peptides found in a number of
species, and represent one of the primary effector defense molecules against invading microorganisms. The sole
human cathelicidin, human cathelicidin antimicrobial peptide of 18 kDA (hCAP18), from which the active form,
LL-37, is proteolytically cleaved, is primarily stored in the specific granules of neutrophils and cleaved into the
active form by proteinase-3. LL-37 can also be produced and secreted by macrophages, lymphocytes and epithelial
cells [72].
Studies have shown that deficiency in LL-37 in humans leads to an increased susceptibility to infection [73], and
mice deficient in the murine cathelicidin (mCRAMP) also display an increased susceptibility to both bacterial and
viral infections of the airway tract, skin, urinary tract and gut [74,75,76]. On the contrary, exogenous delivery of
LL-37 in murine models offered enhanced clearance and reduced mortality in lethal influenza infection [77].
The antimicrobial properties of cathelicidins have been attributed to their highly cationic charge, which allows
for the interaction with negatively charged bacterial and viral membranes leading to the formation of pores, and
their hydrophobicity which helps the integration of the peptides into the microbial membranes. Cathelicidins have
shown potent antiviral activity against a number of viruses (reviewed in [70]) but the exact mechanism of action is
still not fully elucidated. It is clear that the underlying antiviral mechanism of cathelicidins appears to be partly
due to direct effects on the virus envelope, and this has been extensively shown in in vitro studies. Both LL-37, and
the murine cathelicidin mCRAMP, have shown the ability to damage the viral envelope of vaccinia virus, influenza
A virus (IAV) and HSV [77,78,79,80]. LL-37 has also been shown to target viral envelope proteins inhibiting dengue
virus entry into host cells [81].
However, studies have also revealed that cathelicidins have the ability to inactivate nonenveloped viruses, such
as adenovirus and RV [70,80,82]. In the context of RV, it was found that optimal inhibition of virus replication
was reached when the virus was directly exposed to the peptide prior to infection of cells. However, studies with
other viral pathogens have shown that host cell pretreatment or delayed treatment with exogenous LL-37 also
inhibited RSV and IAV replication to an extent [83,84,85]. In vivo studies have also demonstrated the ability of
LL-37 to modulate inflammatory responses to viral infections by inhibiting excessive inflammation in IAV-infected
mice [77]. This indicates that the mechanisms underpinning cathelicidins antiviral activity are complex and that
direct interaction with virus particles allows peptide-mediated damage of, or binding to, the viral envelope may be
a key requirement for this activity. However, interactions with host cells and modulation of the inflammatory and
innate antiviral response could also be of critical importance in the activities of these peptides.
We and others have shown that exogenous LL-37, or vitamin D-mediated cathelicidin production, has potent
direct antiviral activity against RV [82,86,87], including cathelicidins from other mammalian species, such as the
porcine cathelicidin, protegrin-1, and the ovine cathelicidin SMAP-29 [82]. This indicates that the antiviral activity
of cathelicidins is not species-specific against human RV. To further investigate the mechanism underpinning LL-37
activity, we assessed the ability of LL-37 to induce cell death in RV-infected airway epithelial cells as previously we
had reported that LL-37 induced apoptotic cell death of Pseudomonas aeruginosa–infected lung epithelial cells [88].
In contrast to these observations, LL-37 did not induce apoptosis or necrosis in RV-infected airway epithelial
cells [82]. In addition to its direct antiviral activity, LL-37 has also shown the ability to modulate inflammation [89],
which may prove to be a key property in the development of therapeutics that modulate the inflammatory response
to viral infections.
Vitamin D is known for its positive effects on bone mineralization and calciummetabolism, and severe deficiency
has classically been linked to rickets.Mounting evidence now points to a key immunomodulatory role for vitaminD
and to a link between vitamin D deficiency and increased susceptibility to acute viral infections [90]. Furthermore,
despite conflicting reports and heterogeneity within studies, a recent systematic review encompassing 10933
participants in 25 randomized controlled trials concluded that vitamin D supplementation reduced the risk
of acute respiratory infection, with stronger protective effects in patients with baseline 25-hydroxyvitamin D
levels < 25 nmol/l [91].
Humans primarily obtain vitamin D from solar exposure and from the diet. Solar ultraviolet B radiation converts
7-dehydrocholesterol to previtamin D3, which is rapidly converted to vitamin D3. Vitamin D3 from the skin or the
diet is further converted to 25-hydroxyvitamin-D which circulates in serum and is used to determine the vitamin
D status. Lung epithelial cells and immune cells can convert the circulating, inactive, 25-hydroxyvitamin-D to
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Figure 1. Poly I:C treatment of lung epithelial cell prior to
infection with human RV 1B reduces viral replication. Human
bronchial epithelial (16HBE14o−) cells were treated with 10
μg/ml Poly I:C for 24 h, prior to infection with RV1B (MOI 5) and
incubation for 24 h. Viral RNA copies were quantified by RT-PCR.
Figure is representative of n = 3 independent experiments and
shows total virus RNA copy number compared with control
(untreated). Statistical analysis was performed using a t-test to
compare virus only (untreated) control with virus + Poly I:C
pretreatment (*p ≤ 0.05).
RT-PCR: Reverse transcription-polymerase chain reaction.
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Figure 2. Schematic representation of targets for development of antiviral therapeutics against human RV.
its active form, 1,25(OH)2D or calcitriol, which can engage the nuclear vitamin D receptor (VDR) and mediate
its myriad of actions [92,93,94], revealing an important health problem and the underscoring the possibility of
intervention by vitamin D supplementation.
The immediate consequence of nuclear VDR ligation is the heterodimerization with retinoid X receptor and the
binding to vitamin D responsive elements in promoter regions of responsive genes. These genes include CAMP
and DEFB4, which correspond to human cationic antimicrobial peptide of 18 KDa (hCAP-18/LL-37) and β-
Defensin-2 (HBD2) of which both are HDPs [95]. Induction of LL-37 by vitamin D has been reported in several
cell types, including lung epithelial cells, and of relevance, calcitriol (1,25-(OH)2D3) delivery to human primary
bronchial epithelial cells (HPBEC) 24 h prior to RV-16 infection proved sufficient to reduce viral replication by
2.8-fold in comparison to untreated cells [86]. This effect was also observed in cells from cystic fibrosis patients with a
twofold reduction in virus. Importantly,CAMP but notDEFB4mRNA expression was increased by vitamin D, and
exogenous delivery of 20 μg/ml of recombinant LL-37 recapitulated the antiviral effects observed with vitamin D
delivery. A subsequent study validated the antiviral effect of calcitriol pretreatment on the RV1B serotype, reducing
both viral RNA and virion release from HPBEC [87]. These two studies show that calcitriol induces LL-37 and
that > 20 μg/ml of exogenous LL-37 have a direct antiviral effect on RV, an activity that is conserved to other
mammal cathelicidins [82].
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When a complex and physiological model of fully differentiated HPBEC in an air–liquid interface was used
to address the effects of calcitriol on RV16 replication, no reduction in viral load was observed [96]. However,
clear effects on cell morphology and replication were noted. While the doses of calcitriol used in this study were
lower (10 nM) than above mentioned studies, these differences underscore the importance of the cell and delivery
system used to study vitamin D effects. In this regard, daily delivery of 2 μg of calcitriol in tablet form for 1 week
failed to significantly increase nasal LL-37 concentrations in a double-blind, placebo-controlled study involving
healthy or asthmatic subjects [97]. Interestingly, the same group reported that exposing fully differentiated HPBEC
to proinflammatory cytokines such as TNF-α and IL-1β, prior to vitamin D treatment, lessened the induction
of LL-37. This reduced the overall antimicrobial effects of vitamin D due to an alteration in the metabolic
pathway [98]. These observations indicate that further work in this area is required, particularly in the context of
chronic inflammatory lung diseases, as this finding could limit the benefits of vitamin D supplementation strategies.
Upregulation of endogenous HDP production or the delivery of exogenous cathelicidins or synthetic analogs
represents novel and exciting therapeutic strategies for protecting and treating human RV infections. There is
therefore a need to further investigate the mechanisms behind their ability to inhibit viral infections, and to further
establish the antiRV activity of other families of peptides, including defensins. Understanding how these small
peptides operate could support the development of novel therapeutic strategies for RV and possibly other viral
infections.
Modulation of the host response
Modulation or targeting of host molecules responsible for facilitating infection and viral replication may also
provide a valuable therapeutic avenue for the therapeutic treatment of RV. One area of interest has focused
upon the innate antiviral response, which results in broad range protection from infection, and was attributed
to interferons [99]. Purification and further study of interferons found that they were devoid of inherent antiviral
activity, but stimulated the production of other antiviral molecules [100,101], which led coining of the phrase ‘antiviral
state’. Upon recognition of pathogens by cellular sensors including TLRs and RLRs, the type I IFNs (IFN-α and
IFN-β) and type III IFNs (IFN-λ) are some of the earliest immune mediators to be produced (reviewed in [102]).
Their subsequent binding to the interferon receptor induces expression of several interferon-stimulated genes,
resulting in powerful antiviral and immunomodulatory effects to limit infection [103]. Features of this induced
antiviral state include resistance to viral replication, induction of apoptotic cell death and increased expression
of major histocompatibility complex class I in infected cells. Interferons also have an impact on immune cells,
activating dendritic cells (DCs) and macrophages, and stimulating NK cells to enhance their cytolytic activity [104].
This multifaceted, broad-spectrum protection is key to successful antiviral responses.
Recent studies have shown that RV is detected by different sensors on or within the host cell; components of the
capsid are detected by TLR2; ssRNA genome is detected by TLR7/8 and dsRNA generated during viral replication
is detected by TLR3 in endosomes or RIG-I and MDA5 in the cytosol [105,106]. TLR3 is constitutively expressed
in lung epithelial cells, whereas RIG-I and MDA5 are upregulated in response to infection [107,108]. Importantly,
gene silencing any of the dsRNA sensors using siRNA reduces the cytokine response and increases RV replication,
suggesting a coordinated role for multiple sensors in antiviral responses to RV [109]. In this context, mice lacking
TLR3 exhibit higher loads of RNA viruses and decreased production of type I IFN compared with wild-type
mice [110,111]. Significantly, a case study reported that a child harboring a homozygous missense mutation in the
gene IFIH1, which encodes for MDA5, was highly susceptible to recurrent and life-threatening RV infections [112].
This gene mutation resulted in failure to recognize MDA5-ligands associated with RV infection, leading to reduced
IFN production and therefore increased susceptibility to RV.
In vitro studies have shown that exogenous delivery of 0.1–10 ng/ml interferons (IFN-α, IFN-β, IFN-λ1
or IFN-λ2) reduced RV1A viral copies in HPBECs [113]. Interestingly, the exogenous addition of IFN-β also
suppressed RV16 and RV1B replication in HPBECs isolated from healthy and asthmatic individuals [114,115,116,117].
However, exogenous IFN delivery can also potentially impact the already elevated cytokine levels found during RV
infection [113], thus caution must be exercised with this therapeutic strategy.
Polyinosinic-polycytidylic acid, commonly referred to as Poly I:C, is a dsRNA structure thatmimics intermediates
generated during viral replication. When sensed by TLR-3 or cytoplasmic RLR sensors (MAD5 and RIG-I), Poly
I:C induces a strong interferon response, and prophylactic administration of Poly I:C in vitro or in vivo can enhance
protection against a number of viral infections, including several strains of RV [118,119,120,121].
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In addition to regulating the interferon response, Poly I:C is a powerful inducer of proinflammatory cytokines
and chemokines and has been linked to maturation of DCs, NK cell cytotoxicity and virus-specific T-cell re-
sponses [122,123]. This amplification of innate and adaptive immunity provides protection against a range of viruses,
including influenza, Rift Valley fever virus, rabies virus, SARS-Co-BV and RSV [124,125,126,127,128]. Data from our
own laboratory has shown that pretreatment of bronchial epithelial cells with 10 μg/ml of Poly I:C substantially
affects RV RV1B replication (Figure 1).
Drugs based on Poly I:C or derivatives are being developed as broad-spectrum antivirals and potential adjuvants
for DC-targeted vaccines. Poly I:C stabilized with poly-l-lysine and carboxymethylcellulose, known as poly-ICLC,
has shown efficacy against viruses such as influenza [129] and is also being tested in an HIV vaccine trial (Oncovir,
Inc. and Dalton Pharma Services, ON, Canada). PIKA (NewBiomed PIKA Pte Ltd, Singapore), a chemically
stabilized analog of Poly I:C also reduced influenza virus load in the lungs of infected mice [130]. While its antiviral
effects hold promise for treatment of RV infection, delivery of Poly I:C can, in some instances, lead to increased
bacterial replication (Mycobacterium tuberculosis, Streptococcus pneumoniae and Staphylococcus aureus) and impaired
clearance from the lungs due to prolonged interferon signaling [131,132]. Given that RV is frequently associated with
increased secondary bacterial infections, especially in individuals with chronic obstructive pulmonary disease or
other underlying morbidities, further work is required to determine whether Poly I:C or stabilized analogs are safe
as antiviral therapeutics for RV infection.
A further therapeutic strategy may be targeting of host factors that have been identified as important in the
context of RV replication. For example, both oxysterol binding protein (OSBP) and phosphatidylinositol 4-kinase
III β (PI4KB), have been identified as host proteins involved in picornavirus replication [133,134,135], and studies
focusing upon chemical inhibition of PI4KB with a panel of aminothiazoles have demonstrated potent inhibition
of RV [136]. Equally, novel enviroxime-like compounds as well as other compounds such as itraconozole (mentioned
above) which can target OSBP have also shown promise in inhibiting viral replication [61,62,134,137]. Furthermore,
as both PI4KB and OSBP can act as substrates for protein kinase D (PKD), recent studies have identified PKD as a
key molecule in RV replication and have demonstrated that PKD inhibition can profoundly affect RV replication
at an early stage [138]. Interestingly, the lipid-modifying enzyme PLA2G16 has recently been described as playing
a role in picornavirus replication through enhanced viral protein synthesis [139]. Of note, a very recent study
reported that a novel compound, termed IMP-1088, showed potent inhibitory activity towards multiple strains
of RV at nanomolar concentrations. This particular compound blocked viral replication by targeting the host cell
N-myristoyltransferases NMT1 and NMT2, which are required for the assembly of the viral capsid [140]. Thus,
therapeutic options targeting inhibition or functional modulation of these enzymes, or others involved in viral
protein synthesis, may be of value.
Neutralizing antibodies
RV ssRNA genome is contained within an icosahedral protein capsid comprised of four structural proteins;
three are surface exposed (VP1, VP2 and VP3), and VP4 is buried [141]. RV-specific neutralizing antibodies have
been developed against epitopes found on VP proteins that aim to block virus–receptor interaction, stabilize
the capsid preventing viral uncoating, or cause conformational changes in the capsid inducing premature genome
release [142,143,144]. Other studies have shown that antibodies raised against VP4, specifically the N terminus, had RV
neutralizing activity and, indeed, may be a promising target for therapeutic development [145,146]. Another approach
has been to develop antibodies that bind to the host cell receptors, thereby blocking entry of RV. Targeting ICAM-1
in transgenic mice engineered to overexpress extracellular domains 1 and 2 of human ICAM-1 has been shown to
prevent the entry of two major groups of RV, RV16 and RV14. Reduced cellular inflammation, proinflammatory
cytokine production and virus load was also observed in this model [147]. However, targeting and blockage of other
receptors used by minor group RV, such as the low-density lipoprotein (LDL) receptor, has proved elusive. This is
also the case in the context of the development of a universal ‘anti-RV’ antibody, which is problematic due to the
antigenic diversity of circulating RV. Thus, there remain significant challenges associated with the identification of
new antigenic variants and the fact that around 90% of RV serotypes cannot bind to the murine ICAM-1 receptor.
Development of antibody therapies for the prevention and treatment of other viral infections has been recently
reviewed with several antibodies undergoing preclinical development or in clinical trials for newly emerging viral
pathogens such as Ebola as well as long standing pathogens such as influenza [148]. At present there are no licensed
antibodies for clinical use in RV infection, underscoring the need for alternative therapeutic strategies.
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Conclusion & future perspective
An effective licensed therapeutic treatment for RV remains elusive, despite several decades of intensive work that
has aimed to characterize the activity of a wide range of naturally occurring and synthetic compounds against this
infection. The answer to this problem may lie in manipulation of the host cell response with a view to inhibiting
RV replication and spread. For example, one recent study that screened 50,000 potential antiviral structures, and
subsequently identified and analyzed the compound FA-613 found that it interferes with intracellular pyrimidine
synthesis pathways [149]. Furthermore, the addition of FA-613 to virus-infected cells induced the elevated expression
of antiviral genes, leading to inhibition of RV, influenza, RSV and coronavirus replication. This is an example of a
host–cell focused strategy that could yield promising results in the future.
Another way forward could be the use of peptides that are able to act by blocking receptors, such as ICAM-1 and
LDL, essential for RV binding and entry. Cathelicidins can inactivate nonenveloped viruses, such as adenovirus,
and optimal inhibition of RV replication occurs when the virus is directly exposed to the peptide, suggesting that
peptide binding to a component of the capsid is occurring [70,82]. At present, virtually nothing is known about the
determinants for cathelicidin binding to the viral capsid and a full understanding of this will require fine mapping
of cathelicidin binding sites and identification of the active peptide region.
Many of the therapeutics described herein have been under investigation for decades, but the challenges posed
by this particular pathogen have, thus far, been insurmountable. Encouragingly, a new wave of antiviral peptides
and compounds has been characterized over the past 2–3 years, and thus the potential for developing novel and
effective treatments for targeting RV infection may be closer than ever before (Figure 2).
Executive summary
Human rhinoviruses
• Human rhinoviruses (RVs) are the primary etiological agents of the common cold, but can cause serious illness
and increased hospital admissions in immunocompromised individuals or those with pre-existing respiratory
conditions.
• There is currently no licensed vaccine for RV due to the challenges posed by the antigenic diversity and large
variety of circulating RV serotypes.
Antiviral drugs
• There are a number of broad spectrum antiviral drugs that have been shown to display inhibitory activity against
RV.
• Many of the drugs that have shown the most effective activity are capsid binding compounds.
Host defense peptides
• Host defense peptides, such as cathelicidins, are key components of the mammalian immune system and many
display powerful antiviral activity.
• Cathelicidins from a number of mammalian species possess antiviral activity toward RV.
• Vitamin D metabolites can upregulate host defense molecules and in vitro supplementation in models of RV
infection has been reported to reduce viral replication.
Modulation of the host response
• Interferon is critical in the immune response to RV, and manipulation of the interferon response using exogenous
viral mimics, such as Poly I:C, has been shown to reduce RV replication.
• Identification of host molecules required for viral replication can provide novel targets for antiviral therapy and
compounds that can target these host factors have been shown to affect RV replication.
Future perspective
• Investigation of novel capsid binding compounds or peptides will likely be a key determinant in finding an
effective therapeutic for RV.
• Development of novel therapeutics that interfere with RV binding, entry and replication in the host cell could
yield promising results.
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